Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Clinical trial NCT03975231 · RECRUITING

Trial details

NCT number: NCT03975231
Sponsor: City of Hope Medical Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

BRAF NP_004324.2:p.V600E BRAF V600K Mutation Present Thyroid Gland Anaplastic Carcinoma

Start date: 2020-09-14
Primary completion: 2027-10-05
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.